{"doc_id": "si-2022-0679-reg-1", "parent_doc_id": "si-2022-0679", "section_id": "reg-1", "section_label": "Regulation 1.", "si_number": "S.I. No. 679 of 2022", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2022, "heading": "1. These Regulations may be cited as the Health Products Regulatory", "text_raw": "1. These Regulations may be cited as the Health Products Regulatory \n\nAuthority (Fees) Regulations 2022.", "text_norm": "1 regulation may cited health product regulatory authority (fees) regulation 2022", "start_char": 592, "end_char": 699, "source_path": "downloads\\2022\\2022_0681.pdf", "extraction_method": "pdfminer", "checksum": "sha256:1bc55d545103062e367213d33e4d3ba2d4e478c4eb1532eb54c29b2565f0aa8a", "cross_refs": []}
{"doc_id": "si-2022-0679-reg-2", "parent_doc_id": "si-2022-0679", "section_id": "reg-2", "section_label": "Regulation 2.", "si_number": "S.I. No. 679 of 2022", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2022, "heading": "In these Regulations—", "text_raw": "2. \n\nIn these Regulations— \n\n“Act of 1995” means the Irish Medicines Board Act 1995 (No. 29 of \n1995); \n\n“Act of 2006” means the Irish Medicines Board (Miscellaneous \nProvisions) Act 2006 (No. 3 of 2006); \n\n“active substances register” has the meaning assigned to it by \nRegulation 3(1) (inserted by Regulation 3(a) of the Medicinal Products \n(Control of Manufacture) (Amendment) Regulations 2013 (S.I. No. 163 \nof 2013)) of the Medicinal Products (Control of Manufacture) \nRegulations 2007 (S.I. No. 539 of 2007); \n\n“authorised representative” means a person established within the \nEuropean Economic Area who, explicitly designated by \nthe \nmanufacturer, acts for the manufacturer and may be addressed by \nauthorities and bodies in the European Economic Area instead of the \nmanufacturer with respect to the European Communities (Medical \nDevices) Regulations 1994 (S.I. No. 252 of 1994), the European \nCommunities (Active Implantable Medical Devices) Regulations 1994 \n(S.I. No. 253 of 2004), or the European Communities (In Vitro \nDiagnostic Medical Devices) Regulations 2001 (S.I. No. 304 of 2001), \nor has the meaning assigned to it by— \n\n(a) Article 2(32) of the Medical Devices Regulation, or \n\n(b) Article 2(25) of the IVD Medical Devices Regulation, \n\nas applicable; \n\n“Authority” means the Health Products Regulatory Authority; \n\n“breeder authorisation” has the meaning assigned to it by Regulation \n3(1) of the Protection of Animals Regulations; \n\n“broker” means a person carrying out the brokering of medicinal \nproducts, as defined in Regulation 4(1) (as amended by Regulation 3(a) \n\nNotice of the making of this Statutory Instrument was published in \n“Iris Oifigiúil” of 20th December, 2022. \n\n \n \n \n \n \n \n \n\f[679] 3 \n\nof the Medicinal Products (Control of Wholesale Distribution) \n(Amendment) Regulations 2013 (S.I. No. 164 of 2013)) of the Control \nof Wholesale Distribution Regulations; \n\n“brokers register” has the meaning assigned to it by Regulation 4(1) (as \namended by Regulation 3(a) of the Medicinal Products (Control of \nWholesale Distribution) (Amendment) Regulations 2013) of the \nControl of Wholesale Distribution Regulations; \n\n“certificate of free sale” means – \n\n(a) \n\n(b) \n\n(c) \n\na certificate of free sale issued under section 4(1)(k)(ii) (as \namended by section 11(a)(iii) of the Act of 2006) of the Act of \n1995, \n\na certificate of free sale issued under Article 60 of the Medical \nDevices Regulation, or \n\na certificate of free sale issued under Article 55 of the IVD \nMedical Devices Regulation; \n\n“certificate of registration” has the meaning assigned to it by \nRegulation 3(1) of the Control of Placing on the Market Regulations; \n\n“certificate of traditional-use registration” has the meaning assigned to \nit by Regulation 3(1) of the Control of Placing on the Market \nRegulations; \n\n“certification of documents” means the certification, under section \n4(1)(k)(ii) (as amended by section 11(a)(iii) of the Act of 2006) of the \nAct of 1995, of documents not being certificates of free sale or export \ncertificates; \n\n“complex dossier” refers to an application accompanied by a full \ndossier in accordance with Directive 2001/83/EC; \n\n“Control of Placing on the Market Regulations” means the Medicinal \nProducts (Control of Placing on the Market) Regulations 2007 (S.I. No. \n540 of 2007); \n\n“Control of Wholesale Distribution Regulations” means the Medicinal \nProducts (Control of Wholesale Distribution) Regulations 2007 (S.I. \nNo. 538 of 2007); \n\n“decentralised procedure” means the decentralised procedure for human \nmedicinal products provided for in Directive 2001/83/EC; \n\n“device” means – \n\n(a) \n\n(b) \n\n(c) \n\n(d) \n\n(e) \n\na medical device, \n\nan accessory for a medical device, \n\na product listed in Annex XVI to the Medical Devices \nRegulation, provided that the Medical Devices Regulation \napplies to such product pursuant to Article 1(2) thereof, \n\nan in vitro diagnostic medical device, or \n\nan accessory for an in vitro diagnostic medical device, \n\n \n\f4 [679] \n\nbut does not include- \n\n(i) \n\na product or other substance excluded by Article 1(6)(b) to \n(i) of the Medical Devices Regulation, \n\n(ii) a product or other substance excluded from the scope of \nthe IVD Medical Devices Regulation by Article 1(3) \nthereof, \n\n(iii) a device referred to in the second subparagraph of Article \n1(8), (9) or (10) of the Medical Devices Regulation, or \n\n(iv) an in-house device; \n\n“Directive 2001/83/EC” means Directive 2001/83/EC of the European \nParliament and of the Council of 6 November 20011; \n\n“distributor”, in the context of devices, means any natural or legal \nperson in the supply chain, other than the manufacturer or the importer, \nthat makes a device available on the market, up until the point of \nputting into service; \n\n“export certificate” means an export certificate issued under section \n4(1)(k)(ii) (as amended by section 11(a)(iii) of the Act of 2006) of the \nAct of 1995; \n\n“European Union Reference Laboratory” means a laboratory designated \nunder Article 100 of the IVD Medical Devices Regulation. \n\n“follow-up \ninspections; \n\ninspections” means \n\ninspections other \n\nthan \n\nroutine \n\n“homeopathic medicinal product” has the meaning assigned to it by \nRegulation 3(1) of the Control of Placing on the Market Regulations; \n\n“importer”, in the context of devices, means any natural or legal person \nestablished within the European Economic Area that places a device \nfrom a third country on the market in the European Economic Area; \n\n“individual authorisation” means an authorisation granted to an \nindividual under Part 8 of the Protection of Animals Regulations; \n\n“investigational medicinal product” has the meaning assigned to it by \nRegulation 3(1) of the Medicinal Products (Control of Manufacture) \nRegulations 2007; \n\n“in vitro diagnostic medical device” has the meaning assigned to it \nby— \n\n(a) Article 2(2) of the IVD Medical Devices Regulation, or \n\n(b) Regulation 2(1) of the European Communities (In Vitro \nDiagnostic Medical Devices) Regulations 2001 (S.I. No. 304 of \n2001), \n\nas applicable; \n\n1 OJ No. L 311, 28.11.2001, p. 67. \n\n \n \n\f[679] 5 \n\n“IVD Medical Devices Regulation” means Regulation (EU) 2017/746 \nof the European Parliament and of the Council of 5 April 20172 as \namended by Regulation (EU) 2022/112 of the European Parliament and \nof the Council of 25 January 2022; \n\n“listed organisation” has the meaning assigned to it by Regulation 4(1) \n(as amended by Regulation 3 of the Medicinal Products (Prescription \nand Control of Supply) (Amendment) (No. 4) Regulations 2021 (S.I. \nNo. 81 of 2021)) of the Medicinal Products (Prescription and Control of \nSupply) Regulations 2003 (S.I. No. 540 of 2003); \n\n“manufacturer”, in the context of devices, means a person who \nassembles, packages, processes, fully refurbishes or labels one or more \nready-made products or assigns to them their intended purpose as a \ndevice with a view to their being placed on the market under his or her \nown name, but not including a person which assembles or adapts \ndevices already on the market to their intended purpose for an \nindividual patient, or has the meaning assigned to it by— \n\n(a) Regulation 2(1) of \n\nthe European Communities (Medical \n\nDevices) Regulations 1994, \n\n(b) Regulation 2(1) of \n\nthe European Communities \n\n(Active \n\nImplantable Medical Devices) Regulations 1994, \n\n(c) \n\n by Regulation 2(1) of the European Communities (In vitro \nDiagnostic Medical Devices) Regulations 2001, \n\n(d) Article 2(30) of the Medical Devices Regulation, or \n\n(e) Article 2(23) of the IVD Medical Devices Regulation, \n\nas applicable; \n\n“manufacturer’s authorisation” has the meaning assigned to it by \nRegulation 3(1) of the Medicinal Products (Control of Manufacture) \nRegulations 2007; \n\n“manufacturing facility”, in the context of devices, means a place where \nan entity, which does not place devices on the market under its own \nname or under its own trademark— \n\n(a) manufactures a device, \n\n(b) manufactures one or more critical components of a device to a \n\nset of specifications, \n\n(c) \n\n(d) \n\ncarries out packaging activities in relation to a device, or \n\ncarries out labelling activities in relation to a device; \n\n“marketing authorisation” means a marketing authorisation granted \npursuant to the Control of Placing on the Market Regulations; \n\n“medical device” has the meaning— \n\n2 OJ No. L 117, 5.5.2017, p. 176. \n\n \n \n \n\f6 [679] \n\n(a) \n\n(b) \n\n(c) \n\n(d) \n\nassigned to it by Article 2(1) of the Medical Devices Regulation, \n\nassigned to it by Article 2(2) of the IVD Medical Devices \nRegulation, \n\nassigned to the term “device” by Regulation 2(1) of the \nEuropean Communities (Medical Devices) Regulations 1994, or \n\nassigned to the term “device” by Regulation 2(1) of the \nEuropean Communities (Active Implantable Medical Devices) \nRegulations 1994, \n\nas applicable; \n\n“Medical Devices Regulation” means Regulation (EU) 2017/745 of the \nEuropean Parliament and of the Council of 5 April 20173, as amended \nby Regulation (EU) 2020/561 of the European Parliament and of the \nCouncil of 23 April 20204 \n\nrecognition procedure” means \n\n“mutual \nrecognition \nprocedure for human medicinal products provided for in Directive \n2001/83/EC; \n\nthe mutual \n\n“national rules scheme” means the national rules governing the granting \nof marketing authorisation in respect of homeopathic medicinal \nproducts, as provided in Regulation 11 of the Control of Placing on the \nMarket Regulations; \n\n“notified body” means, in relation to any task, a body designated and \nnotified in respect of that task in accordance with the European \nCommunities (Medical Devices) Regulations 1994, the European \nCommunities (Active Implantable Medical Devices) Regulations 1994, \nor the European Communities (In Vitro Diagnostic Medical Devices) \nRegulations 2001, or has the meaning assigned to it by— \n\n(a) Article 2(42) of the Medical Devices Regulation, or \n\n(b) Article 2(34) of the IVD Medical Devices Regulation, \n\nas applicable; \n\n“organ establishment authorisation” means an authorisation granted \npursuant to Regulation 6 of the European Union (Quality and Safety of \nHuman Organs Intended for Transplantation) Regulations 2012 (S.I. \nNo. 325 of 2012); \n\n“parallel import licence” has the meaning assigned to it by Regulation \n3(1) of the Control of Placing on the Market Regulations; \n\n“project” and “project authorisation” have the meanings assigned to \nthem by Regulation 3(1) of the Protection of Animals Regulations; \n\n“Protection of Animals Regulations” means the European Union \n(Protection of Animals used for Scientific Purposes) Regulations 2012 \n(S.I. No. 543 of 2012); \n\n3 OJ No. L 117, 5.5.2017, p. 1. \n4 OJ No. L 130, 24.4.2020, p. 18. \n\n \n \n\f[679] 7 \n\n“reduced dossier – complex” refers to an application for a generic \nmedicinal product accompanied by a reduced dossier but containing \nadditional data in circumstances required by Directive 2001/83/EC; \n\n“reduced dossier – standard” refers to an application for a generic \nmedicinal product accompanied by a reduced dossier in accordance \nwith Directive 2001/83/EC; \n\n“service item” means an application for a medicinal product designated \nby the Authority as qualifying for a reduced application fee on the basis \nthat the product has limited but important uses for which no alternative \nauthorised product exists; \n\n“subsequent extension applications” means applications in relation to \nadditional pharmaceutical forms and strengths of a medicinal product, \nmade subsequent to the first application in relation to that product; \n\n“supplier authorisation” has the meaning assigned to it by Regulation \n3(1) of the Protection of Animals Regulations; \n\n“system or procedure pack producer” means a natural or legal person \nreferred to in— \n\n(a) Article 22(1), (2) or (3) of the Medical Devices Regulation, or \n(b) Article 12 of Council Directive 93/42/EEC of 14th June 19935, \n\nas applicable; \n\n“switching applications” means applications for a change in the \nclassification of medicinal products under Title VI of Directive \n2001/83/EC; \n\n“traditional herbal medicinal product” has the meaning assigned to it by \nRegulation 3(1) of the Control of Placing on the Market Regulations; \n\n“type IA variation”, “type IB variation” and “type II standard variation” \nrefer to classifications by the Authority in accordance with Commission \nRegulation (EC) No. 1234/2008 of 24 November 20086; \n\n“user authorisation” has the meaning assigned to it by Regulation 3(1) \nof the Protection of Animals Regulations; \n\n“wholesaler’s authorisation” has the meaning assigned to it by \nRegulation 4(1) of the Medicinal Products (Control of Wholesale \nDistribution) Regulations 2007.", "text_norm": "2 regulations-- act 1995 mean irish medicine board act 1995 (no 29 1995) act 2006 mean irish medicine board (miscellaneous provisions) act 2006 (no 3 2006) active substance register meaning assigned regulation 3(1) (inserted regulation 3(a) medicinal product (control manufacture) (amendment) regulation 2013 (s.i no 163 2013)) medicinal product (control manufacture) regulation 2007 (s.i no 539 2007) authorised representative mean person established within european economic area explicitly designated manufacturer act manufacturer may addressed authority body european economic area instead manufacturer respect european community (medical devices) regulation 1994 (s.i no 252 1994) european community (active implantable medical devices) regulation 1994 (s.i no 253 2004) european community (in vitro diagnostic medical devices) regulation 2001 (s.i no 304 2001) meaning assigned by-- (a) article 2(32) medical device regulation (b) article 2(25) ivd medical device regulation applicable authority mean health product regulatory authority breeder authorisation meaning assigned regulation 3(1) protection animal regulation broker mean person carrying brokering medicinal product defined regulation 4(1) (as amended regulation 3(a) notice making statutory instrument published iris oifigiuil 20th december 2022 679 3 medicinal product (control wholesale distribution) (amendment) regulation 2013 (s.i no 164 2013)) control wholesale distribution regulation broker register meaning assigned regulation 4(1) (as amended regulation 3(a) medicinal product (control wholesale distribution) (amendment) regulation 2013) control wholesale distribution regulation certificate free sale mean - (a) (b) (c) certificate free sale issued section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 certificate free sale issued article 60 medical device regulation certificate free sale issued article 55 ivd medical device regulation certificate registration meaning assigned regulation 3(1) control placing market regulation certificate traditional-use registration meaning assigned regulation 3(1) control placing market regulation certification document mean certification section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 document certificate free sale export certificate complex dossier refers application accompanied full dossier accordance directive 2001 83 ec control placing market regulation mean medicinal product (control placing market) regulation 2007 (s.i no 540 2007) control wholesale distribution regulation mean medicinal product (control wholesale distribution) regulation 2007 (s.i no 538 2007) decentralised procedure mean decentralised procedure human medicinal product provided directive 2001 83 ec device mean - (a) (b) (c) (d) (e) medical device accessory medical device product listed annex xvi medical device regulation provided medical device regulation applies product pursuant article 1(2) thereof vitro diagnostic medical device accessory vitro diagnostic medical device 4 679 include- (i) product substance excluded article 1(6)(b) (i) medical device regulation (ii) product substance excluded scope ivd medical device regulation article 1(3) thereof (iii) device referred second subparagraph article 1(8) (9) (10) medical device regulation (iv) in-house device directive 2001 83 ec mean directive 2001 83 ec european parliament council 6 november 20011 distributor context device mean natural legal person supply chain manufacturer importer make device available market point putting service export certificate mean export certificate issued section 4(1)(k)(ii) (as amended section 11(a)(iii) act 2006) act 1995 european union reference laboratory mean laboratory designated article 100 ivd medical device regulation follow-up inspection inspection mean inspection routine homeopathic medicinal product meaning assigned regulation 3(1) control placing market regulation importer context device mean natural legal person established within european economic area place device third country market european economic area individual authorisation mean authorisation granted individual part 8 protection animal regulation investigational medicinal product meaning assigned regulation 3(1) medicinal product (control manufacture) regulation 2007 vitro diagnostic medical device meaning assigned by-- (a) article 2(2) ivd medical device regulation (b) regulation 2(1) european community (in vitro diagnostic medical devices) regulation 2001 (s.i no 304 2001) applicable 1 oj no l 311 28.11.2001 p 67 679 5 ivd medical device regulation mean regulation (eu) 2017 746 european parliament council 5 april 20172 amended regulation (eu) 2022 112 european parliament council 25 january 2022 listed organisation meaning assigned regulation 4(1) (as amended regulation 3 medicinal product (prescription control supply) (amendment) (no 4) regulation 2021 (s.i no 81 2021)) medicinal product (prescription control supply) regulation 2003 (s.i no 540 2003) manufacturer context device mean person assembles package process fully refurbishes label one ready-made product assigns intended purpose device view placed market name including person assembles adapts device already market intended purpose individual patient meaning assigned by-- (a) regulation 2(1) european community (medical devices) regulation 1994 (b) regulation 2(1) european community (active implantable medical devices) regulation 1994 (c) regulation 2(1) european community (in vitro diagnostic medical devices) regulation 2001 (d) article 2(30) medical device regulation (e) article 2(23) ivd medical device regulation applicable manufacturer authorisation meaning assigned regulation 3(1) medicinal product (control manufacture) regulation 2007 manufacturing facility context device mean place entity place device market name trademark-- (a) manufacture device (b) manufacture one critical component device set specification (c) (d) carry packaging activity relation device carry labelling activity relation device marketing authorisation mean marketing authorisation granted pursuant control placing market regulation medical device meaning-- 2 oj no l 117 5.5.2017 p 176 6 679 (a) (b) (c) (d) assigned article 2(1) medical device regulation assigned article 2(2) ivd medical device regulation assigned term device regulation 2(1) european community (medical devices) regulation 1994 assigned term device regulation 2(1) european community (active implantable medical devices) regulation 1994 applicable medical device regulation mean regulation (eu) 2017 745 european parliament council 5 april 20173 amended regulation (eu) 2020 561 european parliament council 23 april 20204 recognition procedure mean mutual recognition procedure human medicinal product provided directive 2001 83 ec mutual national rule scheme mean national rule governing granting marketing authorisation respect homeopathic medicinal product provided regulation 11 control placing market regulation notified body mean relation task body designated notified respect task accordance european community (medical devices) regulation 1994 european community (active implantable medical devices) regulation 1994 european community (in vitro diagnostic medical devices) regulation 2001 meaning assigned by-- (a) article 2(42) medical device regulation (b) article 2(34) ivd medical device regulation applicable organ establishment authorisation mean authorisation granted pursuant regulation 6 european union (quality safety human organ intended transplantation) regulation 2012 (s.i no 325 2012) parallel import licence meaning assigned regulation 3(1) control placing market regulation project project authorisation meaning assigned regulation 3(1) protection animal regulation protection animal regulation mean european union (protection animal used scientific purposes) regulation 2012 (s.i no 543 2012) 3 oj no l 117 5.5.2017 p 1 4 oj no l 130 24.4.2020 p 18 679 7 reduced dossier - complex refers application generic medicinal product accompanied reduced dossier containing additional data circumstance required directive 2001 83 ec reduced dossier - standard refers application generic medicinal product accompanied reduced dossier accordance directive 2001 83 ec service item mean application medicinal product designated authority qualifying reduced application fee basis product limited important us alternative authorised product exists subsequent extension application mean application relation additional pharmaceutical form strength medicinal product made subsequent first application relation product supplier authorisation meaning assigned regulation 3(1) protection animal regulation system procedure pack producer mean natural legal person referred in-- (a) article 22(1) (2) (3) medical device regulation (b) article 12 council directive 93 42 eec 14th june 19935 applicable switching application mean application change classification medicinal product title vi directive 2001 83 ec traditional herbal medicinal product meaning assigned regulation 3(1) control placing market regulation type ia variation type ib variation type ii standard variation refer classification authority accordance commission regulation (ec) no 1234 2008 24 november 20086 user authorisation meaning assigned regulation 3(1) protection animal regulation wholesaler authorisation meaning assigned regulation 4(1) medicinal product (control wholesale distribution) regulation 2007", "start_char": 699, "end_char": 13390, "source_path": "downloads\\2022\\2022_0681.pdf", "extraction_method": "pdfminer", "checksum": "sha256:1bc55d545103062e367213d33e4d3ba2d4e478c4eb1532eb54c29b2565f0aa8a", "cross_refs": []}
{"doc_id": "si-2022-0679-reg-3", "parent_doc_id": "si-2022-0679", "section_id": "reg-3", "section_label": "Regulation 3.", "si_number": "S.I. No. 679 of 2022", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2022, "heading": "3. Subject to Regulation 4, there shall be paid to the Authority in respect", "text_raw": "3. Subject to Regulation 4, there shall be paid to the Authority in respect \nof each and every matter set out in column 1 of the Schedule the corresponding \nfee set out in column 2 of the Schedule. \n\n5 OJ No. L 169, 12.7.1993, p. 1. \n6 OJ No. L 334, 12.12.2008, p. 7. \n\n \n \n \n \n\f8 [679]", "text_norm": "3 subject regulation 4 shall paid authority respect every matter set column 1 schedule corresponding fee set column 2 schedule 5 oj no l 169 12.7.1993 p 1 6 oj no l 334 12.12.2008 p 7 8 679", "start_char": 13390, "end_char": 13679, "source_path": "downloads\\2022\\2022_0681.pdf", "extraction_method": "pdfminer", "checksum": "sha256:1bc55d545103062e367213d33e4d3ba2d4e478c4eb1532eb54c29b2565f0aa8a", "cross_refs": []}
{"doc_id": "si-2022-0679-reg-4", "parent_doc_id": "si-2022-0679", "section_id": "reg-4", "section_label": "Regulation 4.", "si_number": "S.I. No. 679 of 2022", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2022, "heading": "4. The Authority may, in circumstances where it considers it appropriate", "text_raw": "4. The Authority may, in circumstances where it considers it appropriate \nto do so, waive, remit or refund, either in whole or in part, any fee that would \notherwise be payable to it under Regulation 3.", "text_norm": "4 authority may circumstance considers appropriate waive remit refund either whole part fee would otherwise payable regulation 3", "start_char": 13679, "end_char": 13884, "source_path": "downloads\\2022\\2022_0681.pdf", "extraction_method": "pdfminer", "checksum": "sha256:1bc55d545103062e367213d33e4d3ba2d4e478c4eb1532eb54c29b2565f0aa8a", "cross_refs": []}
{"doc_id": "si-2022-0679-reg-5", "parent_doc_id": "si-2022-0679", "section_id": "reg-5", "section_label": "Regulation 5.", "si_number": "S.I. No. 679 of 2022", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2022, "heading": "5. The Health Products Regulatory Authority (Fees) Regulations 2021", "text_raw": "5. The Health Products Regulatory Authority (Fees) Regulations 2021 \n\n(S.I. No. 744 of 2021) are revoked. \n\n \n \n\f[679] 9", "text_norm": "5 health product regulatory authority (fees) regulation 2021 (s.i no 744 2021) revoked 679 9", "start_char": 13884, "end_char": 14007, "source_path": "downloads\\2022\\2022_0681.pdf", "extraction_method": "pdfminer", "checksum": "sha256:1bc55d545103062e367213d33e4d3ba2d4e478c4eb1532eb54c29b2565f0aa8a", "cross_refs": []}
{"doc_id": "si-2022-0679-schedule", "parent_doc_id": "si-2022-0679", "section_id": "schedule", "section_label": "SCHEDULE", "si_number": "S.I. No. 679 of 2022", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2022, "heading": "COLUMN 1", "text_raw": "SCHEDULE \n\nCOLUMN 1 \n\n COLUMN 2 \n\nFees for national applications for marketing authorisations \n\n € \n\nComplex dossier \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nReduced dossier – complex \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nReduced dossier – standard \n\nNational application \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nSubsequent extension applications \n\nFirst additional form \n\nEach additional form (same time) \n\nFirst additional strength (existing form) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nFees for applications for marketing authorisations using mutual \nrecognition procedure and decentralised procedure \n\nComplex dossier \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\n22,235 \n\n7,785 \n\n1,110 \n\n4,445 \n\n16,675 \n\n7,785 \n\n1,110 \n\n4,445 \n\n11,120 \n\n7,785 \n\n1,110 \n\n4,445 \n\n11,120 \n\n7,785 \n\n3,335 \n\n1,110 \n\n4,445 \n\n15,565 \n\n5,560 \n\n1,110 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f10 [679] \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \n\napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \n\nMember States \n\nReduced dossier – complex \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \n\napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \n\nMember States \n\nReduced dossier – standard \n\nMutual recognition incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nOutgoing mutual recognition supplement \n\nOutgoing mutual recognition supplement – mutual recognition \n\napplied for within twelve months of the national procedure ending \n\nDecentralised incoming \n\nDecentralised outgoing \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\n16,675 \n\n16,675 \n\n22,235 \n\n55,590 \n\n7,785 \n\n1,110 \n\n1,670 \n\n11,120 \n\n5,560 \n\n1,110 \n\n16,675 \n\n11,120 \n\n16,675 \n\n44,470 \n\n7,785 \n\n1,110 \n\n1,670 \n\n7,785 \n\n4,445 \n\n1,110 \n\n11,120 \n\n6,670 \n\n11,120 \n\n28,905 \n\n7,785 \n\n1,110 \n\n \n \n \n\f[679] 11 \n\nAdditional supplement where there are 15 or more concerned \n\n1,670 \n\nMember States \n\nSubsequent extension applications \n\nMutual recognition incoming (first additional form) \n\nMutual recognition incoming (first additional strength) \n\nMutual recognition incoming (subsequent additional strength) \n\nOutgoing mutual recognition/decentralised supplement (additional \n\n7,785 \n\n2,225 \n\n1,110 \n\n3,335 \n\nform) \n\nOutgoing mutual recognition/decentralised supplement (additional \n\n1,110 \n\nstrength) \n\nDecentralised incoming (first additional form) \n\nDecentralised outgoing (first additional form) \n\nEach additional form (same time) \n\nFirst additional strength (existing form) \n\nEach additional strength (same time) \n\nAdditional supplement where there are 15 or more concerned \n\nMember States \n\nSwitching applications \n\nSwitching applications \n\nFees for parallel import licences \n\nApplication fee - per country at the same time or by \n\nvariation \n\nEach additional strength per country \n\nEach additional form per country \n\nParallel imports - dual pack registration \n\nDual pack registration of parallel imports - each additional \n\nstrength or form \n\nParallel imports where the originator is not on the Irish \n\nmarket \n\nChange of ownership per product range \n\n11,120 \n\n28,905 \n\n7,785 \n\n3,335 \n\n1,110 \n\n1,670 \n\n5,670 \n\n2,040 \n\n605 \n\n605 \n\n1,020 \n\n605 \n\n6,125 \n\n645 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n\f12 [679] \n\nFees for variations to national marketing authorisations \n\nType IB variation \n\nType IB variation - reduced rate \n\nType II complex variation \n\nType II complex variation – reduced rate \n\nType II standard variation \n\nType II standard variation - reduced rate \n\nNotifications under Article 61(3) of Directive 2001/83/ EC \n\nNotifications under Article 61(3) of Directive 2001/83/EC - reduced \n\nrate \n\nMultiple variations capped fee (per product range) \n\nMultiple variations capped fee (per product) \n\nWorksharing capped fee \n\n570 \n\n290 \n\n3,185 \n\n 620 \n\n620 \n\n310 \n\n305 \n\n155 \n\n5,880 \n\n3,800 \n\n6,370 \n\nFees for variations to marketing authorisations under mutual recognition \nprocedure and decentralised procedure \n\nType IA variation outgoing mutual recognition / decentralised \n\n305 \n\nsupplement \n\nType IB variation outgoing mutual recognition / decentralised \n\n425 \n\nsupplement \n\nType IB variation - mutual recognition incoming \n\nType IB variation - mutual recognition incoming - reduced rate \n\nType II complex variation - outgoing mutual recognition / \n\n415 \n\n215 \n\n645 \n\ndecentralised \n\nSupplement \n\nType II complex variation - mutual recognition incoming \n\n2,200 \n\nType II complex variation – mutual recognition incoming – reduced \n\n415 \n\nrate \n\nType II standard variation - mutual recognition incoming \n\nType II standard variation - mutual recognition incoming - reduced \n\nrate \n\nType II standard variation - outgoing mutual recognition / \n\ndecentralised \n\n415 \n\n215 \n\n415 \n\n \n \n\f[679] 13 \n\nSupplement \n\nNotifications made under Article 61(3) of Directive 2001/83/EC \n\nNotifications made under Article 61(3) of Directive 2001/83/EC – \n\n305 \n\n155 \n\nreduced rate \n\nFees for the granting of a marketing authorisation on transfer to another \ncompany \n\nChange of ownership - related company – 1st marketing \n\n1,100 \n\nauthorisation within a range \n\nChange of ownership - related company – each additional marketing \n\n390 \n\nauthorisation within a range \n\nChange of ownership - non-related company – 1st marketing \n\n1,615 \n\nauthorisation within a range \n\nChange of ownership - non-related company – each additional \n\n390 \n\nmarketing authorisation within a range \n\nOther fees relating to the granting of marketing authorisations \n\nService item \n\nNotification to become a listed organisation \n\nNotification Fee \n\nFees for applications for wholesaler’s authorisations \n\nApplication fee \n\nVariation to authorisation - minor site technical \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\n745 \n\n10 \n\n680 \n\n490 \n\n265 \n\n735 \n\n \n \n \n \n \n \n \n \n\f14 [679] \n\nFees for applications for manufacturer’s authorisations \n\nApplication fee \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\nVariation to authorisation – fast track \n\n2,265 \n\n340 \n\n945 \n\n1,335 \n\nFees for applications in relation to brokers register and active substances \nregister \n\nRegistration fee – importers and distributors of active substances and \n\n305 \n\nbrokers \n\nRegistration fee – manufacturers of active substances \n\nImmediate notification of a change which may impact on the quality \n\nor safety of the active substances \n\nNotification of an administrative change to the active substances \n\nregister \n\nNotification of any change to the brokers register \n\n540 \n\n945 \n\n170 \n\n170 \n\nFees for applications for organ establishment authorisations \n\nApplication charge \n\nVariation to authorisation – administrative \n\nVariation to authorisation – technical \n\nAppeal to amend/revoke an authorisation \n\n2,265 \n\n340 \n\n945 \n\n610 \n\nScientific opinion on the non-viability of the cells/tissue, donation, \n\n 3,270 \n\nprocurement testing \n\n \n \n \n \n \n \n \n \n \n \n \n\fFees for transferring of authorisation/registration to another company \n\nManufacturer’s authorisation and organ establishment \n\n[679] 15 \n\nauthorisation \n\nRelated company \n\nUnrelated company \n\nWholesaler’s authorisation, registration on brokers register and \n\nregistration on active substances register \n\nRelated company \n\nUnrelated company \n\nFees for applications in relation to cosmetic products \n\nCertificates of free sale – standard (4 certificates per request) \n\nCertificates of free sale – fast track (4 certificates per request) \n\nDuplicate certificates of free sale – each (available at time of initial \n\nrequest) \n\n1,355 \n\n2,265 \n\n 445 \n\n680 \n\n180 \n\n340 \n\n25 \n\nFees for applications in relation to homeopathic medicinal products \n\nNew national / decentralised registration standard charge - single \n\n830 \n\nstock \n\nNew national / decentralised registration standard charge - 2 or more \n\n1,245 \n\nstocks \n\nNew application - national rules scheme standard fee - single stock \n\nNew application - national rules scheme standard fee - 2 or more \n\nstocks \n\nMutual recognition incoming application standard fee - single stock \n\nMutual recognition incoming application standard fee - 2 or more \n\nstocks \n\nOutgoing mutual recognition / decentralised supplement \n\nNational variation – registration and national rules scheme \n\nNational variation – reduced rate – registrations and national rules \n\nscheme \n\n1,245 \n\n1,835 \n\n555 \n\n830 \n\n690 \n\n415 \n\n205 \n\n \n \n \n \n \n \n \n \n \n \n\f16 [679] \n\nMutual recognition incoming variation \n\nMutual recognition incoming variation - reduced rate \n\nVariation – outgoing mutual recognition / decentralised supplement \n\nBulk variation for multiple changes to the Masterfile \n\n280 \n\n135 \n\n205 \n\n2,495 \n\nFees for applications in relation to traditional herbal medicinal products \n\nNational applications for certificates of traditional-use \n\nregistration \n\nNational application \n\nNational application where there is a monograph \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\nAdditional drug master file submitted \n\nExtension applications \n\nFirst additional form \n\nEach additional form (same time) \n\nFirst additional strength \n\nEach additional strength (same time) \n\nApplications for certificates of traditional-use registration under \n\nmutual recognition procedure and decentralised procedure \n\nMutual recognition incoming \n\nMutual recognition incoming - each additional form (same time) \n\nMutual recognition incoming - each additional strength (same time) \n\nOutgoing mutual recognition / decentralised supplement \n\nDecentralised outgoing/incoming \n\nEach additional form (same time) \n\nEach additional strength (same time) \n\n5,990 \n\n3,675 \n\n4,985 \n\n645 \n\n3,985 \n\n5,990 \n\n4,985 \n\n2,705 \n\n645 \n\n4,185 \n\n2,800 \n\n645 \n\n5,445 \n\n5,990 \n\n4,985 \n\n645 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\fTraditional herbal medicinal products – national variations \n\nType IB variation – national \n\nType IB variation – reduced rate \n\nType II standard variation \n\nType II standard variation – reduced rate \n\nType II complex variation \n\nBulk variation for multiple changes \n\nTraditional herbal medicinal products – mutual recognition \n\nvariations \n\nType IB variation – mutual recognition incoming \n\nType IB variation – mutual recognition incoming - reduced rate \n\nType IB variation – outgoing mutual recognition supplement \n\nType II standard – mutual recognition incoming \n\nType II standard – mutual recognition incoming - reduced rate \n\nType II standard – outgoing mutual recognition supplement \n\nType II complex – mutual recognition incoming \n\nType II complex – outgoing mutual recognition supplement \n\nFees for export certificates and certification of documents \nStandard \n\nFast track \n\nAnnual maintenance fees \n\nMarketing authorisations and registrations \n\nFirst 10 marketing authorisations \n\nAdditional marketing authorisation \n\nDormant marketing authorisation \n\nParallel import licence \n\nParallel import licence - Dual pack \n\nCertificate of registration - homeopathic medicinal products \n\n[679] 17 \n\n460 \n\n235 \n\n490 \n\n245 \n\n2,570 \n\n5,145 \n\n330 \n\n170 \n\n340 \n\n330 \n\n170 \n\n330 \n\n1,760 \n\n510 \n\n180 \n\n340 \n\n795 \n\n990 \n\n463 \n\n135 \n\n65 \n\n65 \n\nCertificate of traditional-use registration - traditional herbal medicinal \n\n135 \n\nproducts \n\nManufacturer’s authorisations \n\n \n \n \n \n \n \n \n \n \n \n\f18 [679] \n\nMajor site (more than 250 employees) \n\nLarge site (150-250 employees) \n\nMedium site (50-149 employees) \n\nSmall site (less than 50 employees) \n\nHomeopathic manufacturing site \n\nWholesaler’s authorisations \n\nLarge full line \n\nMedium full line / short line \n\nSmall short line \n\nMinor site / Procure & supply \n\nActive substances register \n\nActive substances distributor \n\nActive substances importer \n\nActive substances manufacturer \n\nOrgan establishment authorisations \n\nMajor establishment (more than 250 employees) \n\nLarge establishment (150-250 employees) \n\nMedium establishment (50-149 employees) \n\nSmall establishment (less than 50 employees) \n\nMinor establishment (less than 5 employees) \n\nFees in relation to protection of animals used for scientific purposes \n\nProject fees \n\nProject application without ethical approval \n\nFast track project application \n\n23,980 \n\n16,350 \n\n10,900 \n\n4,905 \n\n1,225 \n\n3,395 \n\n1,930 \n\n735 \n\n490 \n\n305 \n\n610 \n\n1,225 \n\n20,415 \n\n13,610 \n\n9,075 \n\n4,535 \n\n1,225 \n\n2,270 \n\n2,100 \n\n \n \n \n \n \n \n \n \n \n \n \n \n\fBreeder/Supplier/User Authorisation fees \n\nBand 1: Small establishment with no animal facilities or \n\nestablishment with 1-3 individual authorisation holders \n\nBand 2: Establishment with 4-10 individual authorisation holders \n\nBand 3: Establishment with 11-20 individual authorisation holders \n\nBand 4: Establishment with 21-40 individual authorisation holders \n\nBand 5: Establishment with 41-70 individual authorisation holders \n\nBand 6: Establishment with 71-100 individual authorisation holders \n\n[679] 19 \n\n330 \n\n655 \n\n1,005 \n\n1,900 \n\n2,890 \n\n3,860 \n\nBand 7: Establishment with 101-150 individual authorisation holders \n\n6,530 \n\nBand 8: Establishment with 151 – 200 individual authorisation \n\n9,500 \n\nholders \n\nBand 9: Establishment with >201 individual authorisation holders \n\n12,470 \n\nIndividual authorisation fees \n\nApplication fee \n\nAnnual fee \n\nOnce-off authorisation - procedural training for a period of two \n\nmonths or less (reduced fee) \n\nFees for follow-up inspections \n\nPer day (per member of the inspection team) \n\nPart of day (per hour, per member of the inspection team) \n\n315 \n\n315 \n\n110 \n\n1,825 \n\n260 \n\nInspection/Audit fees (other than inspections in relation to the protection \n\nof animals used for scientific purposes) \n\nPer day (per member of the inspection team) \n\nPart of day (per hour, per member of the inspection team) \n\nInspection cancellation/rescheduling fee \n\n1,825 \n\n260 \n\n500 \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f20 [679] \n\nEnforcement fees \n\nManufacturers \n\nMajor site (more than 250 employees) \n\nLarge site (150-250 employees) \n\nMedium site (50-149 employees) \n\nSmall site (less than 50 employees) \n\nWholesalers \n\nLarge full line \n\nMedium full line / short line \n\nMarketing authorisation / parallel import licence holders \n\n> 50 marketing authorisations / parallel import licences \n\n31-50 marketing authorisations / parallel import licences \n\n16-30 marketing authorisations / parallel import licences \n\n6-15 marketing authorisations / parallel import licences \n\n2,940 \n\n2,205 \n\n735 \n\n245 \n\n735 \n\n245 \n\n3,860 \n\n1,225 \n\n735 \n\n245 \n\n(Note: Companies classed as both manufacturer and wholesaler are charged the \n\nhigher of the two applicable charges. Marketing authorisation holders pay the \n\nmarketing authorisation holder fee \n\nin addition \n\nto any manufacturer’s \n\nauthorisation / wholesaler’s authorisation fee.) \n\nFees in relation to devices \n\nManufacturer or system and procedure pack producer or manufacturing \n\nfacility located in Ireland – annual fees \n\nManufacturer or system and procedure pack producer or \n\n30,600 \n\nmanufacturing facility - with more than 150 employees \n\nManufacturer or system and procedure pack producer or \n\n20,400 \n\nmanufacturing facility - with 100-150 employees \n\nManufacturer or system and procedure pack producer or \n\n15,300 \n\nmanufacturing facility - with 50-99 employees \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[679] 21 \n\nManufacturer or system and procedure pack producer or \n\n 5,100 \n\nmanufacturing facility - with 16-49 employees \n\nManufacturer or system and procedure pack producer or \n\n 1,275 \n\nmanufacturing facility - with 5-15 employees \n\nManufacturer or system and procedure pack producer or \n\n 250 \n\nmanufacturing facility - with less than 5 employees or annual \n\nturnover of less than €500,000 \n\nAuthorised Representatives – annual fees \n\nType I Authorised Representative – representing a non-EU \n\n1,100 \n\nmanufacturer that manufactures low risk* devices (fee per \n\nmanufacturer) \n\nType II Authorised Representative – representing a non-\n\n1,500 \n\nEU manufacturer that manufactures high risk** devices or \n\na mix of high risk** & low risk* devices (fee per \n\nmanufacturer) \n\nCap on type I Authorised Representative \n\nCap on type II Authorised Representative \n\n5,500 \n\n 7,500 \n\n(Note: * low risk devices means Class I general medical devices (as described \n\nin Council Directive 93/42/EEC of 14 June 19936 (‘MDD’) / the Medical \n\nDevices Regulation (‘MDR’)) and/or general category IVDs (as described in \n\nDirective 98/79/EC of the European Parliament and of the Council of 27 \n\nOctober 19982 (‘IVDD’)) / Class A (as described in the IVD Medical Devices \n\nRegulation (‘IVDR’).) \n\n(Note: ** high risk devices means Class IIa, IIb, III general medicinal devices \n\n(as described in MDD/MDR), active implantable medicinal devices, self-test \n\nIVD, Annex II IVD (as described in IVDD) or Class B, C and D (as described \n\nin IVDR).) \n\nDistributors and Importers – annual fees \n\nLarge distributor/importer (turnover greater than €15 million) \n\nMedium distributor/importer (turnover €3-€15 million) \n\n4,590 \n\n2,550 \n\n \n \n \n \n \n\f22 [679] \n\nSmall distributor/importer (turnover under €3 million) \n\nDistributor/importer turnover less than €500,000 \n\n1,275 \n\n 250 \n\nAdditional supplement – Entities acting as both a distributor and \n\n1,000 \n\nimporter where turnover is more than €3 million \n\nNotified Body – annual fees \n\n 5,100 \n\nSummary evaluation review fees \n\nDevices using starting materials for which a TSE certificate of \n\n2,500 \n\nsuitability has been submitted \n\nDevices using starting materials for which a TSE certificate of \n\n5,000 \n\nsuitability has not been submitted \n\nEuropean Union Reference Laboratories \n\nEuropean Union Reference Laboratory \n\n(EURL) Application \n\n2,700 \n\nVerification \n\nCertificates of free sale or letters confirming the location of the \n\nmanufacturing facility in Ireland for Devices \n\nCertificate of free sale/letter confirming the location of the \n\n255 \n\nmanufacturing facility in Ireland (4 certificates per request) \n\nEach additional certificate of free sale/letter confirming the location of \n\n25 \n\nthe manufacturing facility in Ireland – (available at time of request) \n\nLetter confirming that a device or a list of devices are registered with the \n\n120 \n\nHPRA \n\nRegistration of Devices \n\nOnline Registration – Administration fee \n\n140 \n\nClinical Investigations and IVDR performance studies \n\nClass III and Class IIb medical devices, including relevant MDR \n\n4,300 \n\nAnnex XVI clinical investigations \n\nClass IIa and Class I devices, including relevant MDR Annex \n\n1,900 \n\n \n \n \n \n \n \n \n \n \n \n \n \n\f[679] 23 \n\nXVI clinical investigations \n\nNotifications and substantial modifications to notifications in \n\n200 \n\naccordance with MDR article 74(1), Article 82, IVDR Article \n\n58(2) and IVDR Article 70(1) \n\nApplication for authorisation of in vitro diagnostic medical \n\n2,500 \n\ndevice (IVD) performance study under IVDR Article 58(1) (first \n\nsubmission) and PMPF study under IVDR Article 70(2) \n\nNotification of Performance study involving Companion \n\nDiagnostic IVD using left over samples (IVDR Article 58(2)) \n\nSubstantial modifications and technical amendment to a \n\npreviously approved clinical investigation/performance study \n\n265 \n\n1,240 \n\nResubmission of a clinical investigation/performance study \n\n1,900 \n\nfollowing a withdrawal or objection or if the application has \n\nlapsed \n\nResubmission of a clinical investigation/performance study - \n\n510 \n\nAcademic Sponsor \n\nDetermination of classification within the medical devices regulations \n\nDetermination not requiring a complex technical review (one \n\n280 \n\ndevice per request) \n\nComplex classification requests \n\nArbitration Fee \n\nAppeal of a classification opinion \n\n1,020 \n\n5,000 \n\n600 \n\nDesignation Fee for a Notified Body \n\nInitial designation of a notified body and to the re-assessment of \n\n10,200 \n\nthe notified body under the new Device Regulations 745 and 746 \n\nof 2017 \n\nExtensions to the scope (per extension) \n\nMedicinal Product / Medical Device - Drug Consultation Fees \n\nNew active substance \n\nEstablished active in new therapeutic area \n\n5,100 \n\n48,030 \n\n12,005 \n\n \n \n \n \n \n \n \n\f24 [679] \n\nEstablished active and therapeutic area \n\nVariations - Minor \n\nVariations - Major \n\n6,965 \n\n1,010 \n\n4,535 \n\nAssessments under Article 59 of the MDR and Article 54 of the IVDR \n\nAssessment fee \n\nMiscellaneous - Medical Devices \n\nSearch fee of medical devices data base \n\nDaily charge-out rate for Technical Services \n\nHourly charge-out rate for Technical Services \n\nHourly charge-out rate for Administrative Services \n\n4,000 \n\n65 \n\n1,675 \n\n265 \n\n80 \n\nFees in relation to clinical trials under European Communities (Clinical \n\nTrials on Medicinal Products for Human Use) Regulations 2004 (S.I. No. \n\n190 of 2004) \n\nRequest for authorisation under Regulation 14 – Phase I, II, III or IV \n\nclinical trials \n\nInvestigational medicinal product containing an established active \n\n605 \n\nsubstance \n\nInvestigational medicinal product containing a new active substance \n\n1,620 \n\nAmendment to authorisation under Regulation 21 \n\nNotice of amendment \n\nNotice of amendment to include a new investigational medicinal \n\n410 \n\n880 \n\nproduct dossier \n\nFees in relation to clinical trials under European Union (Clinical Trials on \n\nMedicinal Products for Human Use) (Principal) Regulations 2022 (S.I. No. \n\n99 of 2022) \n\nApplications with an investigational medicinal product dossier \n\nMono National \n\nIreland – Reporting Member State \n\n3,420 \n\n8,700 \n\n \n \n \n \n \n \n \n \n \n\f[679] 25 \n\nIreland - Concerned Member State, initial, transitional or additional \n\n3,200 \n\napplications \n\nSupplement – Where Ireland subsequently becomes the Reporting \n\n5,280 \n\nMember State \n\nReporting Member State – 2nd & subsequent waves \n\nNon Commercial/Academic Trials \n\nApplications with no investigational medicinal product dossier \n\nor with a simplified investigational medicinal product dossier \n\nMono National \n\nIreland – Reporting Member State \n\nIreland - Concerned Member State, initial, transitional or additional \n\napplications \n\n1,000 \n\n300 \n\n2,405 \n\n7,500 \n\n2,135 \n\nSupplement – Where Ireland subsequently becomes the Reporting \n\n5,095 \n\nMember State \n\nReporting Member State – 2nd & subsequent waves \n\nNon Commercial/Academic Trials \n\nSubstantial Modifications (Parts I & II or Part I only) – with \n\nthe addition of a new investigational medicinal product dossier \n\nMono National \n\nIreland – Reporting Member State \n\nIreland - Concerned Member State \n\nNon Commercial/Academic Trials \n\nSubstantial Modifications – other \n\nMono National \n\nIreland – Reporting Member State \n\nIreland- Concerned Member State \n\nNon Commercial/Academic Trials \n\nSubstantial Modifications – Part II only \n\nSubstantial Modification \n\nNon Commercial/Academic Trials \n\n1,000 \n\n300 \n\n1,380 \n\n1,600 \n\n1,325 \n\n100 \n\n910 \n\n1,210 \n\n830 \n\n100 \n\n400 \n\n50 \n\n \n \n \n \n \n \n \n \n \n \n \n\f26 [679] \n\nFees for Appeals \n\nAppeal of clinical trial decision – Commercial \n\nAppeal of clinical trial decision – Non-commercial \n\n Fees for Safety Reports \n\nReview of Annual Safety reports/ Drug safety update reports \n\nReview of drug safety update reports where Ireland is the lead \n\nmember state under a work sharing procedure or Safety assessment \n\nmember state (saMS) \n\nFees for Inspections \n\n per day (per member of the inspection team) \n\n per hour (per member of the inspection team) \n\n1,200 \n\n100 \n\n220 \n\n1,125 \n\n1,825 \n\n260 \n\nFees for applications in relation to Exemptions under Article 61(5) of \n\nRegulation (EU) No. 536/2014 of the European Parliament and of the \n\nCouncil7 \n\nRegistration fee \n\nAmendment to registered details \n\n280 \n\n155 \n\nGIVEN under my Official Seal, \n\n15 December, 2022. \n\nSTEPHEN DONNELLY, \nMinister for Health. \n\n7 OJ No. L 158, 27.5.2014, p. 1. \n\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\f[679] 27", "text_norm": "schedule column 1 column 2 fee national application marketing authorisation eur complex dossier national application additional form (same time) additional strength (same time) additional drug master file submitted reduced dossier - complex national application additional form (same time) additional strength (same time) additional drug master file submitted reduced dossier - standard national application additional form (same time) additional strength (same time) additional drug master file submitted subsequent extension application first additional form additional form (same time) first additional strength (existing form) additional strength (same time) additional drug master file submitted fee application marketing authorisation using mutual recognition procedure decentralised procedure complex dossier mutual recognition incoming additional form (same time) additional strength (same time) 22 235 7 785 1 110 4 445 16 675 7 785 1 110 4 445 11 120 7 785 1 110 4 445 11 120 7 785 3 335 1 110 4 445 15 565 5 560 1 110 10 679 outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) additional supplement 15 concerned member state reduced dossier - complex mutual recognition incoming additional form (same time) additional strength (same time) outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) additional supplement 15 concerned member state reduced dossier - standard mutual recognition incoming additional form (same time) additional strength (same time) outgoing mutual recognition supplement outgoing mutual recognition supplement - mutual recognition applied within twelve month national procedure ending decentralised incoming decentralised outgoing additional form (same time) additional strength (same time) 16 675 16 675 22 235 55 590 7 785 1 110 1 670 11 120 5 560 1 110 16 675 11 120 16 675 44 470 7 785 1 110 1 670 7 785 4 445 1 110 11 120 6 670 11 120 28 905 7 785 1 110 679 11 additional supplement 15 concerned 1 670 member state subsequent extension application mutual recognition incoming (first additional form) mutual recognition incoming (first additional strength) mutual recognition incoming (subsequent additional strength) outgoing mutual recognition decentralised supplement (additional 7 785 2 225 1 110 3 335 form) outgoing mutual recognition decentralised supplement (additional 1 110 strength) decentralised incoming (first additional form) decentralised outgoing (first additional form) additional form (same time) first additional strength (existing form) additional strength (same time) additional supplement 15 concerned member state switching application switching application fee parallel import licence application fee - per country time variation additional strength per country additional form per country parallel import - dual pack registration dual pack registration parallel import - additional strength form parallel import originator irish market change ownership per product range 11 120 28 905 7 785 3 335 1 110 1 670 5 670 2 040 605 605 1 020 605 6 125 645 12 679 fee variation national marketing authorisation type ib variation type ib variation - reduced rate type ii complex variation type ii complex variation - reduced rate type ii standard variation type ii standard variation - reduced rate notification article 61(3) directive 2001 83 ec notification article 61(3) directive 2001 83 ec - reduced rate multiple variation capped fee (per product range) multiple variation capped fee (per product) worksharing capped fee 570 290 3 185 620 620 310 305 155 5 880 3 800 6 370 fee variation marketing authorisation mutual recognition procedure decentralised procedure type ia variation outgoing mutual recognition decentralised 305 supplement type ib variation outgoing mutual recognition decentralised 425 supplement type ib variation - mutual recognition incoming type ib variation - mutual recognition incoming - reduced rate type ii complex variation - outgoing mutual recognition 415 215 645 decentralised supplement type ii complex variation - mutual recognition incoming 2 200 type ii complex variation - mutual recognition incoming - reduced 415 rate type ii standard variation - mutual recognition incoming type ii standard variation - mutual recognition incoming - reduced rate type ii standard variation - outgoing mutual recognition decentralised 415 215 415 679 13 supplement notification made article 61(3) directive 2001 83 ec notification made article 61(3) directive 2001 83 ec - 305 155 reduced rate fee granting marketing authorisation transfer another company change ownership - related company - 1st marketing 1 100 authorisation within range change ownership - related company - additional marketing 390 authorisation within range change ownership - non-related company - 1st marketing 1 615 authorisation within range change ownership - non-related company - additional 390 marketing authorisation within range fee relating granting marketing authorisation service item notification become listed organisation notification fee fee application wholesaler authorisation application fee variation authorisation - minor site technical variation authorisation - administrative variation authorisation - technical 745 10 680 490 265 735 14 679 fee application manufacturer authorisation application fee variation authorisation - administrative variation authorisation - technical variation authorisation - fast track 2 265 340 945 1 335 fee application relation broker register active substance register registration fee - importer distributor active substance 305 broker registration fee - manufacturer active substance immediate notification change may impact quality safety active substance notification administrative change active substance register notification change broker register 540 945 170 170 fee application organ establishment authorisation application charge variation authorisation - administrative variation authorisation - technical appeal amend revoke authorisation 2 265 340 945 610 scientific opinion non-viability cell tissue donation 3 270 procurement testing fee transferring authorisation registration another company manufacturer authorisation organ establishment 679 15 authorisation related company unrelated company wholesaler authorisation registration broker register registration active substance register related company unrelated company fee application relation cosmetic product certificate free sale - standard (4 certificate per request) certificate free sale - fast track (4 certificate per request) duplicate certificate free sale - (available time initial request) 1 355 2 265 445 680 180 340 25 fee application relation homeopathic medicinal product new national decentralised registration standard charge - single 830 stock new national decentralised registration standard charge - 2 1 245 stock new application - national rule scheme standard fee - single stock new application - national rule scheme standard fee - 2 stock mutual recognition incoming application standard fee - single stock mutual recognition incoming application standard fee - 2 stock outgoing mutual recognition decentralised supplement national variation - registration national rule scheme national variation - reduced rate - registration national rule scheme 1 245 1 835 555 830 690 415 205 16 679 mutual recognition incoming variation mutual recognition incoming variation - reduced rate variation - outgoing mutual recognition decentralised supplement bulk variation multiple change masterfile 280 135 205 2 495 fee application relation traditional herbal medicinal product national application certificate traditional-use registration national application national application monograph additional form (same time) additional strength (same time) additional drug master file submitted extension application first additional form additional form (same time) first additional strength additional strength (same time) application certificate traditional-use registration mutual recognition procedure decentralised procedure mutual recognition incoming mutual recognition incoming - additional form (same time) mutual recognition incoming - additional strength (same time) outgoing mutual recognition decentralised supplement decentralised outgoing incoming additional form (same time) additional strength (same time) 5 990 3 675 4 985 645 3 985 5 990 4 985 2 705 645 4 185 2 800 645 5 445 5 990 4 985 645 traditional herbal medicinal product - national variation type ib variation - national type ib variation - reduced rate type ii standard variation type ii standard variation - reduced rate type ii complex variation bulk variation multiple change traditional herbal medicinal product - mutual recognition variation type ib variation - mutual recognition incoming type ib variation - mutual recognition incoming - reduced rate type ib variation - outgoing mutual recognition supplement type ii standard - mutual recognition incoming type ii standard - mutual recognition incoming - reduced rate type ii standard - outgoing mutual recognition supplement type ii complex - mutual recognition incoming type ii complex - outgoing mutual recognition supplement fee export certificate certification document standard fast track annual maintenance fee marketing authorisation registration first 10 marketing authorisation additional marketing authorisation dormant marketing authorisation parallel import licence parallel import licence - dual pack certificate registration - homeopathic medicinal product 679 17 460 235 490 245 2 570 5 145 330 170 340 330 170 330 1 760 510 180 340 795 990 463 135 65 65 certificate traditional-use registration - traditional herbal medicinal 135 product manufacturer authorisation 18 679 major site (more 250 employees) large site (150-250 employees) medium site (50-149 employees) small site (less 50 employees) homeopathic manufacturing site wholesaler authorisation large full line medium full line short line small short line minor site procure supply active substance register active substance distributor active substance importer active substance manufacturer organ establishment authorisation major establishment (more 250 employees) large establishment (150-250 employees) medium establishment (50-149 employees) small establishment (less 50 employees) minor establishment (less 5 employees) fee relation protection animal used scientific purpose project fee project application without ethical approval fast track project application 23 980 16 350 10 900 4 905 1 225 3 395 1 930 735 490 305 610 1 225 20 415 13 610 9 075 4 535 1 225 2 270 2 100 breeder supplier user authorisation fee band 1 small establishment animal facility establishment 1-3 individual authorisation holder band 2 establishment 4-10 individual authorisation holder band 3 establishment 11-20 individual authorisation holder band 4 establishment 21-40 individual authorisation holder band 5 establishment 41-70 individual authorisation holder band 6 establishment 71-100 individual authorisation holder 679 19 330 655 1 005 1 900 2 890 3 860 band 7 establishment 101-150 individual authorisation holder 6 530 band 8 establishment 151 - 200 individual authorisation 9 500 holder band 9 establishment 201 individual authorisation holder 12 470 individual authorisation fee application fee annual fee once-off authorisation - procedural training period two month le (reduced fee) fee follow-up inspection per day (per member inspection team) part day (per hour per member inspection team) 315 315 110 1 825 260 inspection audit fee (other inspection relation protection animal used scientific purposes) per day (per member inspection team) part day (per hour per member inspection team) inspection cancellation rescheduling fee 1 825 260 500 20 679 enforcement fee manufacturer major site (more 250 employees) large site (150-250 employees) medium site (50-149 employees) small site (less 50 employees) wholesaler large full line medium full line short line marketing authorisation parallel import licence holder 50 marketing authorisation parallel import licence 31-50 marketing authorisation parallel import licence 16-30 marketing authorisation parallel import licence 6-15 marketing authorisation parallel import licence 2 940 2 205 735 245 735 245 3 860 1 225 735 245 (note company classed manufacturer wholesaler charged higher two applicable charge marketing authorisation holder pay marketing authorisation holder fee addition manufacturer authorisation wholesaler authorisation fee.) fee relation device manufacturer system procedure pack producer manufacturing facility located ireland - annual fee manufacturer system procedure pack producer 30 600 manufacturing facility - 150 employee manufacturer system procedure pack producer 20 400 manufacturing facility - 100-150 employee manufacturer system procedure pack producer 15 300 manufacturing facility - 50-99 employee 679 21 manufacturer system procedure pack producer 5 100 manufacturing facility - 16-49 employee manufacturer system procedure pack producer 1 275 manufacturing facility - 5-15 employee manufacturer system procedure pack producer 250 manufacturing facility - le 5 employee annual turnover le eur500 000 authorised representative - annual fee type authorised representative - representing non-eu 1 100 manufacturer manufacture low risk device (fee per manufacturer) type ii authorised representative - representing non- 1 500 eu manufacturer manufacture high risk device mix high risk low risk device (fee per manufacturer) cap type authorised representative cap type ii authorised representative 5 500 7 500 (note low risk device mean class general medical device (as described council directive 93 42 eec 14 june 19936 ( mdd ) medical device regulation ( mdr )) general category ivds (as described directive 98 79 ec european parliament council 27 october 19982 ( ivdd )) class (as described ivd medical device regulation ( ivdr ).) (note high risk device mean class iia iib iii general medicinal device (as described mdd mdr) active implantable medicinal device self-test ivd annex ii ivd (as described ivdd) class b c (as described ivdr).) distributor importer - annual fee large distributor importer (turnover greater eur15 million) medium distributor importer (turnover eur3-eur15 million) 4 590 2 550 22 679 small distributor importer (turnover eur3 million) distributor importer turnover le eur500 000 1 275 250 additional supplement - entity acting distributor 1 000 importer turnover eur3 million notified body - annual fee 5 100 summary evaluation review fee device using starting material tse certificate 2 500 suitability submitted device using starting material tse certificate 5 000 suitability submitted european union reference laboratory european union reference laboratory (eurl) application 2 700 verification certificate free sale letter confirming location manufacturing facility ireland device certificate free sale letter confirming location 255 manufacturing facility ireland (4 certificate per request) additional certificate free sale letter confirming location 25 manufacturing facility ireland - (available time request) letter confirming device list device registered 120 hpra registration device online registration - administration fee 140 clinical investigation ivdr performance study class iii class iib medical device including relevant mdr 4 300 annex xvi clinical investigation class iia class device including relevant mdr annex 1 900 679 23 xvi clinical investigation notification substantial modification notification 200 accordance mdr article 74(1) article 82 ivdr article 58(2) ivdr article 70(1) application authorisation vitro diagnostic medical 2 500 device (ivd) performance study ivdr article 58(1) (first submission) pmpf study ivdr article 70(2) notification performance study involving companion diagnostic ivd using left sample (ivdr article 58(2)) substantial modification technical amendment previously approved clinical investigation performance study 265 1 240 resubmission clinical investigation performance study 1 900 following withdrawal objection application lapsed resubmission clinical investigation performance study - 510 academic sponsor determination classification within medical device regulation determination requiring complex technical review (one 280 device per request) complex classification request arbitration fee appeal classification opinion 1 020 5 000 600 designation fee notified body initial designation notified body re-assessment 10 200 notified body new device regulation 745 746 2017 extension scope (per extension) medicinal product medical device - drug consultation fee new active substance established active new therapeutic area 5 100 48 030 12 005 24 679 established active therapeutic area variation - minor variation - major 6 965 1 010 4 535 assessment article 59 mdr article 54 ivdr assessment fee miscellaneous - medical device search fee medical device data base daily charge-out rate technical service hourly charge-out rate technical service hourly charge-out rate administrative service 4 000 65 1 675 265 80 fee relation clinical trial european community (clinical trial medicinal product human use) regulation 2004 (s.i no 190 2004) request authorisation regulation 14 - phase ii iii iv clinical trial investigational medicinal product containing established active 605 substance investigational medicinal product containing new active substance 1 620 amendment authorisation regulation 21 notice amendment notice amendment include new investigational medicinal 410 880 product dossier fee relation clinical trial european union (clinical trial medicinal product human use) (principal) regulation 2022 (s.i no 99 2022) application investigational medicinal product dossier mono national ireland - reporting member state 3 420 8 700 679 25 ireland - concerned member state initial transitional additional 3 200 application supplement - ireland subsequently becomes reporting 5 280 member state reporting member state - 2nd subsequent wave non commercial academic trial application investigational medicinal product dossier simplified investigational medicinal product dossier mono national ireland - reporting member state ireland - concerned member state initial transitional additional application 1 000 300 2 405 7 500 2 135 supplement - ireland subsequently becomes reporting 5 095 member state reporting member state - 2nd subsequent wave non commercial academic trial substantial modification (parts ii part only) - addition new investigational medicinal product dossier mono national ireland - reporting member state ireland - concerned member state non commercial academic trial substantial modification - mono national ireland - reporting member state ireland- concerned member state non commercial academic trial substantial modification - part ii substantial modification non commercial academic trial 1 000 300 1 380 1 600 1 325 100 910 1 210 830 100 400 50 26 679 fee appeal appeal clinical trial decision - commercial appeal clinical trial decision - non-commercial fee safety report review annual safety report drug safety update report review drug safety update report ireland lead member state work sharing procedure safety assessment member state (sams) fee inspection per day (per member inspection team) per hour (per member inspection team) 1 200 100 220 1 125 1 825 260 fee application relation exemption article 61(5) regulation (eu) no 536 2014 european parliament council7 registration fee amendment registered detail 280 155 given official seal 15 december 2022 stephen donnelly minister health 7 oj no l 158 27.5.2014 p 1 679 27", "start_char": 14007, "end_char": 38531, "source_path": "downloads\\2022\\2022_0681.pdf", "extraction_method": "pdfminer", "checksum": "sha256:1bc55d545103062e367213d33e4d3ba2d4e478c4eb1532eb54c29b2565f0aa8a", "cross_refs": []}
{"doc_id": "si-2022-0679-explanatory-note", "parent_doc_id": "si-2022-0679", "section_id": "explanatory-note", "section_label": "EXPLANATORY NOTE", "si_number": "S.I. No. 679 of 2022", "title": "2006)) of the Irish Medicines Board Act 1995 (No. 29 of 1995), hereby make", "year": 2022, "heading": "(This note is not part of the instrument and does not purport to be a legal", "text_raw": "EXPLANATORY NOTE \n\n(This note is not part of the instrument and does not purport to be a legal \ninstrument.) \n\nThe purpose of these Regulations is to provide for the revision of fees payable \nto the Health Products Regulatory Authority (formerly the Irish Medicines \nBoard) pursuant to Section 13 of the Irish Medicines Board Act 1995. \n\nThese Regulations revoke the Health Products Regulatory Authority (Fees) \nRegulations 2021 (S.I. No. 744 of 2021). \n\nThese Regulations may be cited as the Health Products Regulatory Authority \n(Fees) Regulations 2022. \n\n \n \n \n \n \n \n \n \n\f28 [679] \n\nBAILE ÁTHA CLIATH \nARNA FHOILSIÚ AG OIFIG AN tSOLÁTHAIR \nLe ceannach díreach ó \nFOILSEACHÁIN RIALTAIS, \nBÓTHAR BHAILE UÍ BHEOLÁIN, \nCILL MHAIGHNEANN, \nBAILE ÁTHA CLIATH 8, \nD08 XAO6 \n\nTeil: 046 942 3100 \nr-phost: publications@opw.ie \n—————— \n\nDUBLIN \nPUBLISHED BY THE STATIONERY OFFICE \nTo be purchased from \nGOVERNMENT PUBLICATIONS, \nMOUNTSHANNON ROAD, \nKILMAINHAM, DUBLIN 8, \nD08 XAO6 \n\nTel: 046 942 3100 \nE-mail: publications@opw.ie \n—————— \n\n€ 6.50 \n\n(DH-456) 75. 12/22. Propylon.", "text_norm": "explanatory note (this note part instrument purport legal instrument.) purpose regulation provide revision fee payable health product regulatory authority (formerly irish medicine board) pursuant section 13 irish medicine board act 1995 regulation revoke health product regulatory authority (fees) regulation 2021 (s.i no 744 2021) regulation may cited health product regulatory authority (fees) regulation 2022 28 679 baile atha cliath arna fhoilsiu ag oifig tsolathair le ceannach direach foilseachain rialtais bothar bhaile ui bheolain cill mhaighneann baile atha cliath 8 d08 xao6 teil 046 942 3100 r-phost publication opw.ie ------------ dublin published stationery office purchased government publication mountshannon road kilmainham dublin 8 d08 xao6 tel 046 942 3100 e-mail publication opw.ie ------------ eur 6.50 (dh-456) 75 12 22 propylon", "start_char": 38531, "end_char": 39601, "source_path": "downloads\\2022\\2022_0681.pdf", "extraction_method": "pdfminer", "checksum": "sha256:1bc55d545103062e367213d33e4d3ba2d4e478c4eb1532eb54c29b2565f0aa8a", "cross_refs": []}
